Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
patent settlements
Pharma
Alkermes grants Teva license to launch generic Vivitrol in 2027
Under the patent settlement, Teva will be able to launch its generic two years ahead of the 2029 patent expiration for Vivitrol.
Zoey Becker
Aug 31, 2023 10:05am
BMS, AZ settle cancer immunotherapy patent suits for $510M
Aug 1, 2023 10:09am
J&J inks Stelara biosim settlement with Alvotech and Teva
Jun 12, 2023 10:20am
Takeda, Daiichi Sankyo, Dizal, Biden and more—Fierce Pharma Asia
Sep 16, 2022 10:15am
AZ-Daiichi, Biogen-Eisai, Hutchmed, Junshi—Fierce Pharma Asia
May 6, 2022 11:35am
AstraZeneca pays Roche $775M to settle Ultomiris patent brawl
Mar 17, 2022 9:40am
